[go: up one dir, main page]

LT2465950T - K-ras mutacijos ir anti-egfr antikūnų terapija - Google Patents

K-ras mutacijos ir anti-egfr antikūnų terapija

Info

Publication number
LT2465950T
LT2465950T LTEP12154109.8T LT12154109T LT2465950T LT 2465950 T LT2465950 T LT 2465950T LT 12154109 T LT12154109 T LT 12154109T LT 2465950 T LT2465950 T LT 2465950T
Authority
LT
Lithuania
Prior art keywords
egfr antibody
antibody therapy
ras mutations
ras
mutations
Prior art date
Application number
LTEP12154109.8T
Other languages
English (en)
Inventor
Daniel Freeman
Todd Juan
Robert Radinsky
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39689242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2465950(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of LT2465950T publication Critical patent/LT2465950T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
LTEP12154109.8T 2007-03-13 2008-03-11 K-ras mutacijos ir anti-egfr antikūnų terapija LT2465950T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90694307P 2007-03-13 2007-03-13

Publications (1)

Publication Number Publication Date
LT2465950T true LT2465950T (lt) 2017-10-10

Family

ID=39689242

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12154109.8T LT2465950T (lt) 2007-03-13 2008-03-11 K-ras mutacijos ir anti-egfr antikūnų terapija

Country Status (21)

Country Link
US (3) US20080293055A1 (lt)
EP (2) EP2121989B2 (lt)
JP (1) JP2010521153A (lt)
AR (1) AR065687A1 (lt)
AU (1) AU2008226803A1 (lt)
CA (1) CA2680326A1 (lt)
CL (1) CL2008000717A1 (lt)
CY (2) CY1115333T1 (lt)
DK (2) DK2465950T3 (lt)
ES (2) ES2458626T5 (lt)
HR (2) HRP20140360T4 (lt)
HU (1) HUE033695T2 (lt)
LT (1) LT2465950T (lt)
MX (1) MX2009009787A (lt)
PE (1) PE20081880A1 (lt)
PL (2) PL2121989T5 (lt)
PT (2) PT2465950T (lt)
RS (2) RS56422B1 (lt)
SI (2) SI2121989T2 (lt)
TW (1) TW200902553A (lt)
WO (1) WO2008112269A2 (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129114B2 (en) * 2005-08-24 2012-03-06 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
RU2008146868A (ru) 2006-05-18 2010-06-27 Кэрис МПИ, Инк.445 Норт Фифс Стрит, 3-ий Флор, Феникс, Аризона 85004, США (US) Система и способ определения персонализированого медицинского вмешательства при болезненном состоянии
TW200904828A (en) * 2007-03-13 2009-02-01 Amgen Inc K-ras and B-raf mutations and anti-EGFr antibody therapy
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
EP2556172A4 (en) 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASES
KR20120140252A (ko) * 2010-04-12 2012-12-28 리스판스 지네틱스, 인크. Ｋｒａｓ 프라이머 및 프로브
US9309556B2 (en) 2010-09-24 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
WO2013071142A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
GB2533006B (en) 2012-09-04 2017-06-07 Guardant Health Inc Systems and methods to detect copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
EP2977464A4 (en) * 2013-03-19 2016-10-19 Toppan Printing Co Ltd PROCEDURE FOR PREDICTING SENSITIVITY TO EGFR HEMMER
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
WO2015175705A1 (en) 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
SG11201805119QA (en) 2015-12-17 2018-07-30 Guardant Health Inc Methods to determine tumor gene copy number by analysis of cell-free dna
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
EP0636186B1 (en) 1992-04-03 1998-11-25 The Perkin-Elmer Corporation Probe composition and method
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1161563A2 (en) 1999-03-15 2001-12-12 PE Corporation (NY) Probe/mobility modifier complexes for multiplex nucleic acid detection
JP2004507226A (ja) 2000-05-30 2004-03-11 ピーイー　コーポレイション　（エヌワイ） ライゲーションおよび増幅の組み合わせを用いて標的核酸を検出するための方法
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
CA2485691A1 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
AU2004248140A1 (en) 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
EP2439285B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
CA2569520C (en) 2004-06-04 2023-03-14 Genentech, Inc. Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab
WO2006047484A2 (en) * 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Molecular analysis of cellular fluid and liquid cytology specimens for clinical diagnosis, characterization, and integration with microscopic pathology evaluation
BRPI0609615A2 (pt) 2005-04-01 2010-04-27 Amgen Inc. métodos de predição da eficácia de tratamento de agente de ligação especìfica a egfr em tratamento de cáncer relacionado com egfr num sujeito, de tratamento do mesmo e de determinação da eficácia de tratamento em paciente
JP2008535508A (ja) * 2005-04-14 2008-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍組織における増大したコピー数のｅｇｆｒ遺伝子に基づく抗ｅｇｆｒ抗体療法
EP1913157B2 (en) 2005-06-28 2016-10-26 Genentech, Inc. Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment
US8703769B2 (en) * 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
US8129114B2 (en) * 2005-08-24 2012-03-06 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US8293501B2 (en) * 2006-09-12 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for performing low background multiplex nucleic acid amplification reactions
TW200904828A (en) * 2007-03-13 2009-02-01 Amgen Inc K-ras and B-raf mutations and anti-EGFr antibody therapy

Also Published As

Publication number Publication date
WO2008112269A2 (en) 2008-09-18
US20120264129A1 (en) 2012-10-18
TW200902553A (en) 2009-01-16
US20080293055A1 (en) 2008-11-27
ES2458626T3 (es) 2014-05-06
US10030270B2 (en) 2018-07-24
DK2121989T3 (da) 2014-04-28
EP2121989A2 (en) 2009-11-25
PL2121989T3 (pl) 2014-07-31
PE20081880A1 (es) 2008-12-31
CA2680326A1 (en) 2008-09-18
CY1119112T1 (el) 2018-02-14
MX2009009787A (es) 2009-09-22
US20190048423A1 (en) 2019-02-14
RS53265B2 (sr) 2022-06-30
AR065687A1 (es) 2009-06-24
RS56422B1 (sr) 2018-01-31
CL2008000717A1 (es) 2008-09-22
EP2121989B1 (en) 2014-01-22
HRP20140360T4 (hr) 2022-06-10
RS53265B (sr) 2014-08-29
WO2008112269A3 (en) 2008-11-20
SI2465950T1 (sl) 2017-11-30
PL2121989T5 (pl) 2023-03-06
SI2121989T1 (sl) 2014-06-30
PT2121989E (pt) 2014-04-30
PL2465950T3 (pl) 2017-12-29
ES2458626T5 (es) 2022-04-29
HUE033695T2 (en) 2017-12-28
DK2121989T4 (da) 2022-06-20
HRP20140360T1 (hr) 2014-05-23
EP2465950B1 (en) 2017-07-12
EP2465950A2 (en) 2012-06-20
AU2008226803A1 (en) 2008-09-18
EP2465950A3 (en) 2013-03-13
US11155876B2 (en) 2021-10-26
CY1115333T1 (el) 2017-01-04
JP2010521153A (ja) 2010-06-24
EP2121989B2 (en) 2022-03-09
HRP20171509T1 (hr) 2017-11-17
SI2121989T2 (sl) 2022-05-31
PT2465950T (pt) 2017-10-17
DK2465950T3 (en) 2017-10-09
ES2635051T3 (es) 2017-10-02

Similar Documents

Publication Publication Date Title
LT2465950T (lt) K-ras mutacijos ir anti-egfr antikūnų terapija
PL2412828T3 (pl) Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
GB0719803D0 (en) Therapeutic compounds and their use
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
GB0803018D0 (en) Therapeutic compounds and their use
ZA200806723B (en) Combination therapy using anti-EGFR and anti-Her2 antibodies
GB0804685D0 (en) Therapeutic compounds and their use
GB0722680D0 (en) Therapeutic compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB2460178B (en) Depsipeptides and their therapeutic use
GB2460181B (en) Depsipeptides and their therapeutic use
IL206420A0 (en) Azetidine derivatives, their preparation and their application in therapy
GB0812913D0 (en) Therapeutic compounds and their use
EP2097085A4 (en) THERAPEUTIC MATERIALS AND METHOD
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
GB2460180B (en) Depsipeptides and their therapeutic use
GB0802128D0 (en) Therapeutic compounds and their use
HK1139182A (en) K-ras and b-raf mutations and anti-egfr antibody therapy
GB0705517D0 (en) Therapeutic compounds and their use
GB0821539D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use
EP2234667A4 (en) DETERMINATION AND METHODS OF ADMINISTERING A TREATMENT
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0819103D0 (en) Raphaine compounds and their use in therapy